(Q38114116)

English

Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.

scientific article published on 03 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chelsea Ma

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

April W Armstrong

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

publication date

3 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Journal of Dermatological Treatment

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

401-408

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Persistent neurotoxicity of systemically administered interferon-alpha

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Mechanisms of Interferon-alpha induced apoptosis in malignant cells

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Cytokines secreted by IL-2-activated lymphocytes induce endogenous nitric oxide synthesis and apoptosis in macrophages

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.3109%2F09546634.2013.813897

21 January 2018

Identifiers

10.3109/09546634.2013.813897

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38114116&oldid=2174683065"